Biogen is relinquishing its ownership of Alzheimer’s treatment Aduhelm, which came under scrutiny after its 2021 approval. The Swiss company, Neurimmune, who developed the drug, will regain full rights to it, and Biogen plans to end a clinical trial meant to prove its benefits. Despite this, Biogen’s CEO praised Aduhelm as a groundbreaking discovery that set the stage for new drugs and reinvigorated investments in medicine. This marks a turning point in Biogen’s history, moving away from Aduhelm after a contentious chapter.
Source link
Biogen walks away from Aduhelm, years after polarizing approval
